Morning Market Losers

shares fell 19.84% to $30.70 after the company issued topline clinical data for second Phase 3 trial of OTX-DP.

shares dipped 5.90% to $44.18 after the company priced an offering of 4 million units at $44.42 per unit.

shares declined 1.87% to $35.97 following the report of sale of 73.4 million shares by the Canadian government.

shares slipped 1.43% to $28.20 after the company announced a proposed 7 million share public offering.

shares slipped 1% to $78.86. Oppenheimer downgraded American Express from Market Perform to Underperform.

shares dropped 0.76% to $68.08 after the company issued details of strategic realignment. The company projected a pretax charge of $785 million in the second quarter and announced its plans to reduce headcount. The company also said it will temporarily halt its stock buyback program.

fell 0.50% to $15.95 after the company reported a wider-than-expected loss for the second quarter and announced its plans to reduce costs.